

## IN THE UNITED STATES PATF

## RADEMARK OFFICE

## PATENT APPLICATION

Inventor(s): IMHOF et al.

Appln. No.: 09

524,531

Series Code ↑

Serial No. ↑

Filed: March 13, 2000

Hon. Commissioner of Patents

Washington, D.C. 20231

Sir:

REPLY/AMENDMENT/LETTER

Group Art Unit 1644

Examiner: J. ROARK

Atty. Dkt. P 264679 LWY09/CM/6

M#

Client Ref

Appln. Title: VASCULAR ADHESION MOLECULES  
AND MODULATION OF HEIR  
FUNCTION

Date: July 29, 2002

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

## FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim		Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
A. <input checked="" type="checkbox"/> NOT made	B. <input type="checkbox"/> Withdrawn						
For B & C See Required Separate Paper (Pat-256)							
2. Total Effective Claims		8	**minus 20	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims		3	***minus 3	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application) add					+ \$280/\$140 =	+ \$0	104/204
5. Original due Date: August 23, 2002		<input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo)	\$110/\$55 =				115/215
		(2 mos)	\$400/\$200 =		+ \$0		116/216
		(3 mos)	\$920/\$460 =				117/217
		(Usable only for ≤ 2mo.OA --- 4 mos)	\$1,440/\$720=				118/218
		(Usable only for 30 day/1mo.OA --- 5 mos)	\$1,960/\$980=				128/228
7. Enter any previous extension fee paid since above original due date and subtract					- \$0		
8. Extension Fee					+ \$0		
9. If Terminal Disclaimer attached, add Rule 20(d) official fee					+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c), add					+ \$180	+ \$0	126
or if Rule 97(d) Request add					+ \$180		126
11. After-Final Request Fee per rules 129(a) and 17(r)					+ \$740/370	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b)					x \$740/370 ea	+ \$0	149/249
13. Request for Continued Examination (RCE)					+ \$740/370	+ \$0	1179/1279
14. Petition fee for					+ \$0		
15. TOTAL FEE =						\$0	
16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".						PLEASE CHARGE OUR DEP. ACCT.	
17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.							
18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.							

Our Deposit Account No. 03-3975)

(Our Order No. 011422 0264679

C#

M#

**CHARGE STATEMENT:** The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP  
Intellectual Property Group

By Atty: Blair E. Taylor

Reg. No. 44,370

1600 Tysons Boulevard

McLean, VA 22102

Tel: (703) 905-2000

Sig:

Blair E. Taylor

Fax:

(703) 905-2500

BEST AVAILABLE COPY

# Notice to Comply

Application No. 01A

Applicant(s)

09/524,531 /

IMHOF ET AL.

Examiner

JUL 29 2002

Art Unit

Jessica H. Roark

1644

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

### Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216  
For CRF Submission Help, call (703) 308-4212  
PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**RECEIVED**

JUL 31 2002

TECH CENTER 1600/2900

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**

**BEST AVAILABLE COPY**